New programme will help MedTech companies get a foot in the door of NHS procurers

MEDTECH companies are being offered a helping hand to penetrate the NHS with the launch of the new innovation programme, Smart Solutions for Healthcare.

The initiative is open to companies and other non-NHS organisations from any country and across any sector and will provide them with a rare opportunity to have their product or service evaluated in an NHS clinical setting.

We need to find smarter solutions and new ways of working and we will be challenging industry and other innovation suppliers to help us do this

Organised by TrusTECH, the North West NHS innovation hub, entries will be assessed by a panel of experts and between four and 10 will eventually be selected to undergo further evaluation.

Programme director, Dr Bryan Griffiths, said “The NHS faces a monumental challenge in the years ahead. We need to find smarter solutions and new ways of working and we will be challenging industry and other innovation suppliers to help us do this.

“In many cases new technologies, devices and services will be required to help change the way care is delivered. Smart Solutions for Healthcare will consider all of these, as well as disruptive system changes which offer entirely new approaches to diagnosis and treatment.”

And he said the panel was particularly looking for solutions to treat long-term conditions such as cancer and heart disease and new approaches that help to deliver healthcare in patients’ communities or homes.

We are specifically interested in new technologies, products, services and the application of scientific advances that enable patients to have a greater role in managing their own health  

“We are specifically interested in new technologies, products, services and the application of scientific advances that enable patients to have a greater role in managing their own health, or help healthcare providers improve staff productivity and eliminate waste,” he added.

“Products or services must address the priority areas of cardiovascular disease, including aneurysm, angina, atherosclerosis, AF, stroke, CVD, heart failure, coronary artery disease, heart attack, venous thromboembolism and hypertension; or long-termconditions such as cancer, diabetes, renal disease, hypothyroidism and epilepsy.”

The closing date for entries is 6 April and more details are available on the website.

Companies